- Home
- BKD vs ADPT Comparison
BKD vs ADPT Comparison
Compare BKD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKD
- ADPT
- Stock Information
- Founded
- BKD 2005
- ADPT 2009
- Country
- BKD United States
- ADPT United States
- Employees
- BKD N/A
- ADPT N/A
- Industry
- BKD Hospital/Nursing Management
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BKD Health Care
- ADPT Health Care
- Exchange
- BKD Nasdaq
- ADPT Nasdaq
- Market Cap
- BKD 1.7B
- ADPT 1.8B
- IPO Year
- BKD 2005
- ADPT 2019
- Fundamental
- Price
- BKD $7.68
- ADPT $12.85
- Analyst Decision
- BKD Buy
- ADPT Strong Buy
- Analyst Count
- BKD 5
- ADPT 8
- Target Price
- BKD $7.80
- ADPT $12.38
- AVG Volume (30 Days)
- BKD 2.7M
- ADPT 1.8M
- Earning Date
- BKD 11-05-2025
- ADPT 08-05-2025
- Dividend Yield
- BKD N/A
- ADPT N/A
- EPS Growth
- BKD N/A
- ADPT N/A
- EPS
- BKD N/A
- ADPT N/A
- Revenue
- BKD $3,051,698,000.00
- ADPT $205,216,000.00
- Revenue This Year
- BKD $8.33
- ADPT $32.76
- Revenue Next Year
- BKD N/A
- ADPT $15.81
- P/E Ratio
- BKD N/A
- ADPT N/A
- Revenue Growth
- BKD 4.23
- ADPT 21.60
- 52 Week Low
- BKD $4.45
- ADPT $3.98
- 52 Week High
- BKD $8.01
- ADPT $13.52
- Technical
- Relative Strength Index (RSI)
- BKD 55.28
- ADPT 57.00
- Support Level
- BKD $7.57
- ADPT $12.62
- Resistance Level
- BKD $7.77
- ADPT $13.25
- Average True Range (ATR)
- BKD 0.19
- ADPT 0.55
- MACD
- BKD 0.01
- ADPT -0.05
- Stochastic Oscillator
- BKD 76.00
- ADPT 58.13
About BKD Brookdale Senior Living Inc.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).